Log In Sign up
The largest database of trusted experimental protocols

Ly3009120

Manufactured by Active Motif
Visit Supplier

LY3009120 is a selective and potent inhibitor of the serine/threonine protein kinase AKT. It inhibits the phosphorylation of AKT, a key regulator of cell growth, survival, and metabolism.

Automatically generated - may contain errors

Lab products found in correlation

Dabrafenib, by GlaxoSmithKline (3 mentions) Vemurafenib, by Plexxikon (3 mentions) Plx8394, by Plexxikon (3 mentions) Lapatinib, by GlaxoSmithKline (3 mentions) Encorafenib, by Novartis (2 mentions) Hygromycin, by Thermo Fisher Scientific (2 mentions) Tak 632, by Selleck Chemicals (2 mentions) Doxycycline d3072, by Merck Group (2 mentions) 4 hydroxytamoxifen 4 oht h7904, by Merck Group (2 mentions) Hygromycin stock solution, by Thermo Fisher Scientific (1 mentions) Doxycycline, by Merck Group (1 mentions) Puromycin, by Thermo Fisher Scientific (1 mentions) Trametinib, by GlaxoSmithKline (1 mentions) Plx7904, by Plexxikon (1 mentions) Lgx818, by Novartis (1 mentions)

3 protocols using ly3009120

1

Multi-Kinase Inhibitor Screening Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
BGB283 and BGB659 were obtained from Beigene. vemurafenib, PLX7904, PLX8394 from Plexxikon. lapatinib, trametinib, dabrafenib from GlaxoSmithKline. LGX818 is from Novartis. LY3009120 purchased from Active Biochem, Doxycycline from Sigma Aldrich, Puromycin, Hygromycin stock solution from Invitrogene., other drugs from Selleckchem. Drugs were dissolved in DMSO to yield 10mM stock and stored at −20°C.
Yao Z., Torres N.M., Tao A., Gao Y., Luo L., Li Q., de Stanchina E., Abdel-Wahab O., Solit D.B., Poulikakos P, & Rosen N. (2015). BRAF mutants evade ERK dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer cell, 28(3), 370-383.
+ Open protocol
+ Expand
2

Comprehensive Drug Treatment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
BGB659 was obtained from Beigene. Vemurafenib and PLX8394 were from Plexxikon. Lapatinib and dabrafenib were from GlaxoSmithKline. TAK632 was from Selleckchem. encorafenib was from Novartis. LY3009120 was purchased from Active Biochem, All these drugs were dissolved in DMSO to yield 10mM stock and stored at −20 °C Doxycycline (D3072) and 4-hydroxytamoxifen (4-OHT) (H7904) were purchased from Sigma Aldrich, Puromycin (A1113802) and Hygromycin (10687010) stock solution was from Thermo Fisher Scientific.
Yao Z., Gao Y., Su W., Yaeger R., Tao J., Na N., Zhang Y., Zhang C., Rymar A., Tao A., Timaul N.M., Mcgriskin R., Outmezguine N.A., Zhao H., Chang Q., Qeriqi B., Barbacid M., de Stanchina E., Hyman D.M., Bollag G, & Rosen N. (2018). RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling. Nature medicine, 25(2), 284-291.
+ Open protocol
+ Expand
3

Comprehensive Drug Treatment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
BGB659 was obtained from Beigene. Vemurafenib and PLX8394 were from Plexxikon. Lapatinib and dabrafenib were from GlaxoSmithKline. TAK632 was from Selleckchem. encorafenib was from Novartis. LY3009120 was purchased from Active Biochem, All these drugs were dissolved in DMSO to yield 10mM stock and stored at −20 °C Doxycycline (D3072) and 4-hydroxytamoxifen (4-OHT) (H7904) were purchased from Sigma Aldrich, Puromycin (A1113802) and Hygromycin (10687010) stock solution was from Thermo Fisher Scientific.
Yao Z., Gao Y., Su W., Yaeger R., Tao J., Na N., Zhang Y., Zhang C., Rymar A., Tao A., Timaul N.M., Mcgriskin R., Outmezguine N.A., Zhao H., Chang Q., Qeriqi B., Barbacid M., de Stanchina E., Hyman D.M., Bollag G, & Rosen N. (2018). RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling. Nature medicine, 25(2), 284-291.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!